Trump issued a fabulous new executive order on Jan. 28 entitled “Protecting Children from Chemical and Surgical Mutilation.” What, you might ask, is meant by ...

Corporation (NASDAQ:NVNO), a medical device company with a market capitalization of $54.5 million, reported interim two-year follow-up data from its pivotal trial of the VenoValve, indicating ...

Q3 2025 Earnings Call Transcript February 5, 2025 Operator: Welcome to McKesson’s Third Quarter Fiscal 2025 Earnings Conference Call. Please be advised that today’s conference is being recorded. At ...

Baxalta spinoff was successful, Baxter's financial results fell substantially in 2022-23 on external pressures, such as inflation and weak medical utilization trends. With medical utilization rising, ...

The military hospital has moved some surgeries to other facilities and rescheduled or deferred more than 200 patient visits.

Direct-to-store model (delivering drugs directly to each retailer’s stores) of distributors are increasingly becoming more popular among retailers (represents 93% of sales in 2017, up from 74% in 2007 ...

Q2 2025 Earnings Call February 4, 2025 8:00 AM ETCompany ParticipantsBen Krasinski - Senior Director, IRMichael J.

U.S. farmers and various trade groups are very apprehensive about not only the potential negative impacts of tariffs on the U ...

Q3 2025 Earnings Conference Call February 5, 2025 8:30 AM ETCompany ParticipantsDavid Galison - Head of Investor ...

USE ONAPGO is a prescription medicine used to treat motor fluctuations (OFF episodes) in adults with advanced Parkinson’s disease (PD). It is not known if ONAPGO is safe and effective in children.

ONAPGO is the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson's diseaseONAPGO is a wearable subcutaneous infusion devi ...

A surgical team at The Medical Center at Bowling Green recently became the first in the Southcentral Kentucky area to use a ...